Personal take on this article: This study evaluates the safety, tolerability, and pharmacokinetics of eteplirsen in boys aged 6 to 48 months with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), is designed to restore dystrophin production. The open-label, dose-escalation trial involved 15 boys divided into two cohorts: one group aged 24 to 48 months and another aged 6 to …

more

    Today, on September 7th, we stand together to recognize the relentless fight against Duchenne Muscular Dystrophy. I want to commend all the brilliant researchers, clinicians, and investors who have poured their energy into advancing treatments and finding cures for this challenging condition. Your dedication is making a difference, and I am honored to be a part of this mission. Exactly four years ago, I made a life-changing decision …

more

    Personal take on this article: The paper explores the vital role of mitochondria in regulating muscle stem cells, particularly satellite cells (SCs), which are crucial for skeletal muscle regeneration. Mitochondria are essential for energy production through oxidative phosphorylation (Oxphos), which supports various metabolic processes and influences SC fate, including their quiescence, activation, self-renewal, and differentiation. This study emphasizes how mitochondrial metabolism adapts to different environmental cues and its …

more

      Revised Threshold A "revised threshold" refers to an updated or adjusted level or criterion used in medical practice or pharmacology, often based on new research, clinical guidelines, or evidence. This could pertain to various measurements, such as diagnostic test results, treatment initiation criteria, or drug dosage limits. For example, if new research suggests that lower blood pressure targets reduce cardiovascular risk, the threshold for initiating antihypertensive therapy …

more

    Personal take on this article:   This document reports on the findings from a Phase 2b clinical trial that evaluated the effects of vamorolone, a novel steroid, and prednisone on adrenal suppression in boys with Duchenne muscular dystrophy (DMD). The study involved 121 steroid-naive boys aged 4 to under 7 years with genetically confirmed DMD, and assessed adrenal function using morning cortisol levels and ACTH-stimulated cortisol levels. Adrenal …

more

  Personal take on this article: Facioscapulohumeral muscular dystrophy (FSHD) is a progressive genetic disorder that primarily affects muscles of the face, shoulder girdle, and upper arms, with the potential to cause severe muscle atrophy over time. The disease is characterized by the aberrant expression of the DUX4 gene due to compromised epigenetic repression of the D4Z4 array, leading to toxic effects in muscle tissue. FSHD can be categorized into …

more

    Personal take on this article: Emery-Dreifuss muscular dystrophy (EDMD) is a rare and genetically complex neuromuscular disorder, characterized by progressive muscle wasting, early-onset contractures, and life-threatening cardiac conduction issues. The disorder presents significant clinical variability, even among family members with the same genetic mutations, complicating its diagnosis and treatment. Traditionally, genome-wide association studies have struggled to identify all the causative mutations due to the disorder's genetic heterogeneity, with …

more

    Personal take on this article:   MitoNEET, a mitochondrial protein, plays a protective role against insulin resistance in muscle cells during iron overload (IO). IO typically leads to an accumulation of iron in mitochondria, which in turn increases reactive oxygen species (ROS) and triggers excessive mitochondrial fission—both of which contribute to insulin resistance. By overexpressing MitoNEET, researchers observed a reduction in mitochondrial iron levels, decreased ROS production, and …

more

    Personal take on this article: Recent developments in Becker muscular dystrophy (BMD) research have focused on improving trial readiness and exploring new treatment strategies. Although BMD has historically been overshadowed by Duchenne muscular dystrophy (DMD), recent advances in diagnostics and natural history studies have highlighted the need for more targeted clinical trials. Improved genetic sequencing has led to more frequent diagnoses of BMD, even in diverse populations, and …

more

    Personal take on this article:   The study investigates the role of high mobility group box protein 1 (HMGB1) as a potential biomarker for Duchenne muscular dystrophy (DMD) by utilizing RNA sequencing in mouse models and human induced pluripotent stem cell (iPSC)-derived skeletal muscle cells. The findings suggest that HMGB1 is elevated in DMD conditions and can be reduced with gene therapy using microdystrophin. This indicates that HMGB1 …

more